Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for severe chronic hand eczema after inadequate response or intolerance to alitretinoin
2019-001561-32Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Response to treatment on Physician Global Assessment. Started Jan 2020; status: active.
02
Drugs
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on 2019-001561-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001561-32.